Brief: Actinium Pharmaceuticals Reports 2022 Financial Results
03/04/2023 12:46
April 3 (Reuters) - Actinium Pharmaceuticals Inc
ATNM.A :
* ACTINIUM PHARMACEUTICALS REPORTS 2022 FINANCIAL RESULTS
AND
HIGHLIGHTS RECENT AND UPCOMING CLINICAL DATA AND MILESTONES
* ACTINIUM PHARMACEUTICALS INC - ON TRACK TO COMMENCE EARLY
ACCESS
PROGRAM AND FILE A BLA SUBMISSION FOR IOMAB-B IN 2H:2023
* ACTINIUM PHARMACEUTICALS INC - STRONG BALANCE SHEET
EXPECTED TO
FUND OPERATIONS THROUGH 2025
* ACTINIUM PHARMACEUTICALS INC - CASH AND CASH EQUIVALENTS
OF
$108.9 MILLION AS OF DECEMBER 31, 2022
* ACTINIUM PHARMACEUTICALS - NET LOSS $33.0 MILLION FOR YEAR
ENDED
DEC 31, 2022, COMPARED WITH $24.8 MILLION FOR YEAR ENDED DEC 31,
2021
Source text for Eikon: ID:nPn9hJG5ma
Further company coverage: ATNM.A
((reuters.briefs@thomsonreuters.com;))
Recent news on Actinium Pharmaceuticals
See all newsBrief: Actinium Pharmaceuticals Announces Actimab-A Intellectual Property And Manufacturing Advances And Provides NYSE American Listing Update
Brief: Actinium Pharmaceuticals - Receives Two Canadian Patent Allowances For Actimab-A And Iomab-Act Programs
Brief: ctinium’s Atnm-400 Shows Strong Efficacy in TNBC, Beats Therapy Resistance at SABCS
Brief: Actinium Pharmaceuticals Says ATNM-400 Shows Superior Efficacy To Xtandi In Prostate Cancer
Brief: Actinium Pharmaceuticals Announces ATNM-400 A Novel Non-PSMA Targeting First In Class Prostate Cancer Radiotherapy Leveraging Actinium-225